Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  wk 45 2 t/m 6 november

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

wk 45 2 t/m 6 november

141 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 »» | Laatste | Omlaag ↓
  5. [verwijderd] 3 november 2009 17:15
    Calmune and Crucell Enter Exclusive Research Collaboration
    Calmune to Use Proprietary Technology Platform to Generate Potent Human Monoclonal Antibodies Against Infectious Diseases

    Press Release
    Source: Calmune Corporation
    On 3:00 am EST, Tuesday November 3, 2009
    Companies:CrucellCrucell Nv
    SAN DIEGO, CA--(Marketwire - 11/03/09) - Calmune Corporation, a privately held biotechnology company developing novel antibodies to address unmet clinical needs, announced today that it has established an exclusive research collaboration with Crucell N.V. (EURONEXT: CRXL) (NASDAQ:CRXL - News) (Swiss:CRX - News), a global biopharmaceutical company based in Leiden, the Netherlands, focusing on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Financial details of the agreement were not disclosed.

    Under this collaboration, Calmune will use SEBVI(TM), a proprietary technology to prepare a panel of potent, high-affinity human monoclonal antibodies (hMabs) against a pre-defined, undisclosed infectious disease target. Crucell will have the option to exclusively license these hMabs for further evaluation as development candidates, and to develop any that meet its required profile. Calmune will receive payments from Crucell at different stages of the discovery and development process, as well as a royalty on sales of products that incorporate antibodies generated by Calmune.

    By exploiting the power of the human immune response, Calmune's SEBVI(TM) technology allows natural, high-affinity, fully human antibodies against microbial targets to be efficiently recovered from Epstein Barr virus-transformed memory B cells.

    Dr. Jaap Goudsmit, Chief Scientific Officer of Crucell, said, "Calmune's demonstrated technological expertise in the generation of potent human monoclonal antibodies is a valuable complement to Crucell's existing research programs and opens the door to the development of new therapeutics for infectious diseases."

    Dr. Anthony Williamson, CEO of Calmune, and Dr. Dennis Burton, Chairman of the Board, commented in a joint statement, "We are delighted to be working together with Crucell, which has an established commitment to developing and marketing therapeutic antibodies against infectious diseases. This collaboration is an important external endorsement of our technology, and we are confident we will be able to deliver candidate antibodies that meet Crucell's requirements. We would like to gratefully acknowledge the support of Tilocor, our principal investor, towards Calmune's emergence as an innovative therapeutic antibody company."

    About Calmune

    Calmune Corporation is a privately held biotechnology company developing antibody therapeutics to address unmet clinical needs. The company was founded in 2006 in San Diego, California, by three members of The Scripps Research Institute. Calmune has two novel technology platforms that provide a rapid means to recover high affinity, fully-human antibodies, and to create novel antibodies with unique structural modifications for targeting hypoimmunogenic epitopes. Calmune has received financing from its principal investor, Tilocor Life Science. Calmune has a growing pipeline of early-stage product candidates in several therapeutic areas. For more information, please see www.calmune.com.

    About Tilocor Life Science

    Tilocor Life Science provides financial support for the Tilocor Group's newly created companies, acquisitions and investments. Co-founded by Professor Stefan Catsicas, former Vice-President of the Swiss Federal Institute of Technology (Lausanne), Tilocor promotes an entrepreneurial approach adapted to the long-term needs of the life science sector. Currently, Tilocor companies focus on infectious diseases, inflammation and cancer with specific therapeutic agents that include human antibodies, intracellular peptides and small chemical entities. www.tilocor.com

    About Crucell

    Crucell N.V. (EURONEXT: CRXL) (NASDAQ:CRXL - News) (Swiss:CRX - News) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6? production technology. The Company licenses its PER.C6? technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea, UK and the U.S. The Company employs over 1200 people.

  6. flosz 3 november 2009 17:40
    di 03 nov 2009, 17:15
    Het overnameseizoen is weer begonnen!
    Nederlandse beurs goedkoop

    AMSTERDAM - „Waarom zou ik überhaupt nog in Nederlandse aandelen beleggen?” is een vraag die ik als fondsmanager van Robeco Hollands Bezit vaak krijg gesteld. Mijn kort door de bocht antwoord hierop is dat Nederlandse aandelen gewoon te goedkoop zijn en een aantal buitengewoon aantrekkelijk is om overgenomen te worden.

    In het kamp van de structurele groeiers zetten wij in op internetbroker Binck en vaccinproducent Crucell. Binck heeft in het veroveren van de Franse markt de komende jaren voldoende groeimogelijkheden en ook Crucell kan met zijn 5-in-1 vaccin in ontwikkelingslanden nog volop groeien. Of ze dit als zelfstandig bedrijf kunnen blijven doen is wat ons betreft nog maar de vraag. Aan interesse uit het buitenland zal het in ieder geval niet liggen: Johnson&Johnson kocht enige weken geleden al 18% in het Leidse bedrijf.
    www.telegraaf.nl/overgeld/experts/hen...
    __Nederlandse_beurs_goedkoop__.html
  12. Barbier 4 november 2009 17:32
    BELLEVUE, Wash., Nov. 4, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a
    biotechnology company specializing in the development of immunotherapeutic
    vaccines for cancer and infectious diseases, has signed a license agreement with
    Crucell N.V.

    Under the license TapImmune may use the proprietary PER.C6(R) cells in its
    development programs. The PER.C6(R) cell line is ideally suited for the
    development and large-scale manufacturing of a multitude of biopharmaceuticals.
    In the use of recombinant vaccines using adenoviral vectors, PER.C6(R) cells do
    not generate replication competent adenoviruses, making it the state-of-the-art
    platform for the large-scale production of adenoviral vectors for clinical
    applications.

    The PER.C6(R) cell line is the best documented cell line for vaccine development
    to date. Its extensive Biologics Master File at the U.S. FDA can be
    cross-referenced by licensees, resulting in simplification and acceleration of
    the IND filing and approval process.

    The partnership between TapImmune and Crucell is important for the production of
    TapImmune's vaccine products. Under the terms of this agreement, Crucell has the
    rights to negotiate a license for TapImmune's TAP technologies for infectious
    disease indications.
  14. risky N 4 november 2009 17:41
    quote:

    callhans schreef:

    [quote=mcking]
    Lijkt wel of de koers niet mag stijgen

    what's new ??
    [/quote]36000 stuks in de eindveiling zonder enig prijsverschil
    Waarom mag de koers niet stijgen? Iedereen staat toch vrij om te kopen of te verkopen. Gisteren iedereen in zak en as en vandaag stijgt de koers 2% en wordt er al weer in complottheorieën gedacht.
  15. [verwijderd] 4 november 2009 17:48
    quote:

    fyx schreef:

    [quote=callhans]
    [quote=mcking]
    Lijkt wel of de koers niet mag stijgen

    what's new ??
    [/quote]36000 stuks in de eindveiling zonder enig prijsverschil
    [/quote]

    Waarom mag de koers niet stijgen? Iedereen staat toch vrij om te kopen of te verkopen. Gisteren iedereen in zak en as en vandaag stijgt de koers 2% en wordt er al weer in complottheorieën gedacht.
    AB'tje!
  18. roloff 4 november 2009 18:23
    quote:

    aossa schreef:

    Handel buiten beurs (aan afgesproken koers) die geofficialiseerd wordt.
    Is waarschijnlijk de reden voor het streng vastzetten van de koers tijdens de handel.
    "Geofficialiseerd" en "afgesproken koers op handel buiten de beurs om",

    Onzin,

    Op € 14.04 zit gewoon een technnisch weerstandsnivo.

    Crucell-Groet,
    Roloff
  19. forum rang 9 josti5 4 november 2009 18:26
    quote:

    rolof schreef:

    [quote=aossa]
    Handel buiten beurs (aan afgesproken koers) die geofficialiseerd wordt.
    Is waarschijnlijk de reden voor het streng vastzetten van de koers tijdens de handel.
    [/quote]

    "Geofficialiseerd" en "afgesproken koers op handel buiten de beurs om",

    Onzin,

    Op € 14.04 zit gewoon een technnisch weerstandsnivo.

    Crucell-Groet,
    Roloff
    Dream on, rolof, en hulde, aossa!
  20. roloff 4 november 2009 18:32
    Kijk maar eens op Binck (de technische analyse aldaar).

    Daar staan onderstaande niveau's al lange tijd vermeld (toeval dus volgens jullie, of voorkennis "Handel buiten beurs aan afgesproken koers").

    Beknopt advies (bron: BinckBank)

    Advies: Negatief

    Weerstand 1 13,86 Steun 1 11,82
    Weerstand 2 14,04 Steun 2 7,40

    Gr. Roloff

141 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 923,71 +0,04%
EUR/USD 1,0818 0,00%
FTSE 100 8.245,37 -0,48%
Germany40^ 18.547,30 -0,56%
Gold spot 2.293,78 0,00%
NY-Nasdaq Composite 17.133,13 -0,23%

Stijgers

Brederode
+1,93%
SYENSQO
+1,74%
Colruyt
+1,18%
Care P...
+1,13%
Orange...
+0,95%

Dalers

VGP
-3,93%
Aedifica
-3,01%
Cofinimmo
-2,63%
WDP
-2,48%
Lotus ...
-2,38%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!